Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Connection

Peter Crooks to Binding Sites

This is a "connection" page, showing publications Peter Crooks has written about Binding Sites.

 
Connection Strength
 
 
 
1.486
 
  1. Penthala NR, Balasubramaniam M, Dachavaram SS, Morris EJ, Bhat-Nakshatri P, Ponder J, Jordan CT, Nakshatri H, Crooks PA. Antitumor properties of novel sesquiterpene lactone analogs as NF?B inhibitors that bind to the IKK? ubiquitin-like domain (ULD). Eur J Med Chem. 2021 Nov 15; 224:113675.
    View in: PubMed
    Score: 0.183
  2. Janganati V, Ponder J, Thakkar S, Jordan CT, Crooks PA. Succinamide derivatives of melampomagnolide B and their anti-cancer activities. Bioorg Med Chem. 2017 07 15; 25(14):3694-3705.
    View in: PubMed
    Score: 0.137
  3. Nickell JR, Culver JP, Janganati V, Zheng G, Dwoskin LP, Crooks PA. 1,4-Diphenalkylpiperidines: A new scaffold for the design of potent inhibitors of the vesicular monoamine transporter-2. Bioorg Med Chem Lett. 2016 07 01; 26(13):2997-3000.
    View in: PubMed
    Score: 0.128
  4. Penthala NR, Ketkar A, Sekhar KR, Freeman ML, Eoff RL, Balusu R, Crooks PA. 1-Benzyl-2-methyl-3-indolylmethylene barbituric acid derivatives: Anti-cancer agents that target nucleophosmin 1 (NPM1). Bioorg Med Chem. 2015 Nov 15; 23(22):7226-33.
    View in: PubMed
    Score: 0.124
  5. Penthala NR, Thakkar S, Crooks PA. Heteroaromatic analogs of the resveratrol analog DMU-212 as potent anti-cancer agents. Bioorg Med Chem Lett. 2015 Jul 15; 25(14):2763-7.
    View in: PubMed
    Score: 0.120
  6. Ding D, Nickell JR, Dwoskin LP, Crooks PA. Quinolyl analogues of norlobelane: novel potent inhibitors of [(3)H]dihydrotetrabenazine binding and [(3)H]dopamine uptake at the vesicular monoamine transporter-2. Bioorg Med Chem Lett. 2015 Jul 01; 25(13):2613-6.
    View in: PubMed
    Score: 0.120
  7. Penthala NR, Ponugoti PR, Nickell JR, Deaciuc AG, Dwoskin LP, Crooks PA. Pyrrolidine analogs of GZ-793A: synthesis and evaluation as inhibitors of the vesicular monoamine transporter-2 (VMAT2). Bioorg Med Chem Lett. 2013 Jun 01; 23(11):3342-5.
    View in: PubMed
    Score: 0.103
  8. Crooks PA, Zheng G, Vartak AP, Culver JP, Zheng F, Horton DB, Dwoskin LP. Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse. Curr Top Med Chem. 2011; 11(9):1103-27.
    View in: PubMed
    Score: 0.088
  9. Vartak AP, Gabriela Deaciuc A, Dwoskin LP, Crooks PA. Quinlobelane: a water-soluble lobelane analogue and inhibitor of VMAT2. Bioorg Med Chem Lett. 2010 Jun 15; 20(12):3584-7.
    View in: PubMed
    Score: 0.084
  10. Vartak AP, Nickell JR, Chagkutip J, Dwoskin LP, Crooks PA. Pyrrolidine analogues of lobelane: relationship of affinity for the dihydrotetrabenazine binding site with function of the vesicular monoamine transporter 2 (VMAT2). J Med Chem. 2009 Dec 10; 52(23):7878-82.
    View in: PubMed
    Score: 0.082
  11. Zheng G, Dwoskin LP, Deaciuc AG, Crooks PA. Stereocontrolled synthesis and pharmacological evaluation of cis-2,6-diphenethyl-1-azabicyclo[2.2.2]octanes as lobelane analogues. J Org Chem. 2009 Aug 21; 74(16):6072-6.
    View in: PubMed
    Score: 0.080
  12. Zheng G, Dwoskin LP, Deaciuc AG, Crooks PA. Synthesis and evaluation of a series of homologues of lobelane at the vesicular monoamine transporter-2. Bioorg Med Chem Lett. 2008 Dec 15; 18(24):6509-12.
    View in: PubMed
    Score: 0.076
  13. Crooks PA, Ayers JT, Xu R, Sumithran SP, Grinevich VP, Wilkins LH, Deaciuc AG, Allen DD, Dwoskin LP. Development of subtype-selective ligands as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release. Bioorg Med Chem Lett. 2004 Apr 19; 14(8):1869-74.
    View in: PubMed
    Score: 0.056
  14. Balasubramaniam M, Mainali N, Bowroju SK, Atluri P, Penthala NR, Ayyadevera S, Crooks PA, Shmookler Reis RJ. Structural modeling of GSK3? implicates the inactive (DFG-out) conformation as the target bound by TDZD analogs. Sci Rep. 2020 10 27; 10(1):18326.
    View in: PubMed
    Score: 0.044
  15. Huang X, Zheng F, Chen X, Crooks PA, Dwoskin LP, Zhan CG. Modeling subtype-selective agonists binding with alpha4beta2 and alpha7 nicotinic acetylcholine receptors: effects of local binding and long-range electrostatic interactions. J Med Chem. 2006 Dec 28; 49(26):7661-74.
    View in: PubMed
    Score: 0.017
  16. Huang X, Zheng F, Crooks PA, Dwoskin LP, Zhan CG. Modeling multiple species of nicotine and deschloroepibatidine interacting with alpha4beta2 nicotinic acetylcholine receptor: from microscopic binding to phenomenological binding affinity. J Am Chem Soc. 2005 Oct 19; 127(41):14401-14.
    View in: PubMed
    Score: 0.015
  17. Geldenhuys WJ, Lockman PR, Nguyen TH, Van der Schyf CJ, Crooks PA, Dwoskin LP, Allen DD. 3D-QSAR study of bis-azaaromatic quaternary ammonium analogs at the blood-brain barrier choline transporter. Bioorg Med Chem. 2005 Jul 01; 13(13):4253-61.
    View in: PubMed
    Score: 0.015
  18. Wilkins LH, Grinevich VP, Ayers JT, Crooks PA, Dwoskin LP. N-n-alkylnicotinium analogs, a novel class of nicotinic receptor antagonists: interaction with alpha4beta2* and alpha7* neuronal nicotinic receptors. J Pharmacol Exp Ther. 2003 Jan; 304(1):400-10.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.